CIK 0000318154 · Large accelerated filer
AMGEN INC
Sign in to watch- Ticker
- AMGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 953540776
- Phone
- (805)447-1000
- Business address
- ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Grygiel Nancy A. SVP & CCO | Grant or award | +2,010 | 9,249 | ||
| 2026-03-03 | Griffith Peter H. EVP & CFO | Grant or award | +12,063 | 54,587 | ||
| 2026-03-03 | Graham Jonathan P EVP & Gen. Counsel & Sec. | Grant or award | +10,723 | 44,478 | ||
| 2026-03-03 | Gordon Murdo EVP, Global Commercial Ops | Grant or award | +13,403 | 56,807 | ||
| 2026-03-03 | Bradway Robert A Chairman, CEO and President | Grant or award | +42,657 | 457,146 | ||
| 2026-03-03 | Busch Matthew C. VP, Finance & CAO | Grant or award | +938 | 4,361 | ||
| 2026-02-26 | Santos Esteban EVP, Operations | Option exercise | +30,501 | $162.60 | $5.0M | 107,119 |
| 2026-02-26 | Santos Esteban EVP, Operations | Sale | −30,501 | $379.12 | $11.6M | 76,618 |
| 2026-02-26 | Santos Esteban EVP, Operations | Option exercise | +24,291 | $177.46 | $4.3M | 100,909 |
| 2026-02-26 | Santos Esteban EVP, Operations | Sale | −24,291 | $379.12 | $9.2M | 76,618 |
| 2026-02-26 | Santos Esteban EVP, Operations | Option exercise · Nqso (Right to Buy) | −30,501 | 0 | ||
| 2026-02-26 | Santos Esteban EVP, Operations | Option exercise · Nqso (Right to Buy) | −24,291 | 0 | ||
| 2026-02-19 | Busch Matthew C. VP, Finance & CAO | Sale | −1,000 | $375.79 | $376K | 3,423 |
| 2026-02-09 | Bradner James E. EVP, Research and Development | Shares withheld for taxes | −2,151 | $384.32 | $827K | 28,331 |
| 2026-02-09 | Bradner James E. EVP, Research and Development | Shares withheld for taxes | −953 | $384.32 | $366K | 27,378 |
| 2025-11-20 | Grygiel Nancy A. SVP & CCO | Option exercise | +1,500 | $177.46 | $266K | 8,725 |
| 2025-11-20 | Grygiel Nancy A. SVP & CCO | Sale | −1,500 | $337.26 | $506K | 7,225 |
| 2025-11-20 | Grygiel Nancy A. SVP & CCO | Option exercise | +1,639 | $162.60 | $267K | 8,864 |
| 2025-11-20 | Grygiel Nancy A. SVP & CCO | Sale | −1,639 | $337.26 | $553K | 7,225 |
| 2025-11-20 | Grygiel Nancy A. SVP & CCO | Option exercise · Nqso (Right to Buy) | −1,500 | 1,970 |
Page 7 of 22 · 430 trades